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Statin use in the secondary prevention of coronary heart disease in
primary care: cohort study and comparison of inclusion and
outcome with patients in randomised trials
L Wei, S Ebrahim, C Bartlett, P G Davey, F M Sullivan, T M MacDonald
Abstract
Objective To compare the social and demographic profiles of
patients who receive statin treatment after myocardial infarction
and patients included in randomised trials. To estimate the
effect of statin use in community based patients on subsequent
all cause mortality and cardiovascular recurrence, contrasting
effects with trial patients.
Design Observational cohort study using a record linkage
database.
Setting Tayside, Scotland (population size and characteristics:
about 400 000, mixed urban and rural).
Subjects 4892 patients were discharged from hospital after
their first myocardial infarction between January 1993 and
December 2001. 2463 (50.3%) were taking statins during an
average follow-up of 3.7 years (3.1% in 1993 and 62.9% in
2001).
Main outcome measures All cause mortality and recurrence of
cardiovascular events.
Results 319 deaths occurred in the statin treated group (age
adjusted rate 4.1 per 100 person years, 95% confidence interval
3.2 to 4.9), and 1200 in the statin untreated group (12.7 per 100
person years, 11.1 to 14.3). More older people and women were
represented in the population of patients treated with statins
than among those recruited into clinical trials (mean age 67.8 v
59.8; women 39.6% v 16.9%, respectively). The effects of statins
in routine clinical practice were consistent with, and similar to,
those reported in clinical trials (adjusted hazard ratio for all
cause mortality 0.69, 95% confidence interval 0.59 to 0.80;
adjusted hazard ratio for cardiovascular recurrence 0.82, 0.71 to
0.95).
Conclusions The community effectiveness of statins in those
groups that were not well represented in clinical trials was
similar to the efficacy of statins in these trials.
Introduction
Statins are effective cholesterol lowering agents and are
prescribed for prevention of cardiovascular events. Several large
clinical trials (the Scandinavian simvastatin survival study (4S),
the cholesterol and recurrent events (CARE) study, the long term
intervention with pravastatin in ischaemic disease (LIPID) study,
and the Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico Prevenzione (GISSI-P) study)1–4 of
secondary prevention of coronary heart disease have shown that
statins reduce the risk of death by about 30%. However, it is com-
mon for clinical trials to apply selection criteria that may protect
the internal validity of the trial at the expense of reducing the
applicability of the trial’s findings to the wider population of
patients seen in routine clinical practice. Consequently, patients
who are prescribed statins in the “real world” may differ system-
atically from those people who receive statins in clinical trials
and may have different outcomes from those reported in trials.
We reviewed the literature relating to the effects of statin
treatment on cardiovascular outcomes, but we found no studies
that directly compared the sociodemographic profile and clinical
outcomes between patients routinely treated in the community
and in clinical trials. However, a recent paper has shown that the
effect of statins prescribed in general practice had similar effects
on serum cholesterol concentrations to that seen in trials.5 We
recently reported a meta-analysis that included 27 secondary
prevention trials of statins published up to December 2001.6 This
analysis showed that the mean age of patients was 59.8, the pro-
portion of female patients was 16.9%, and statins reduced
mortality by 21% (relative risks 0.79, 95% confidence interval
0.73 to 0.85). We characterised those subjects who received statin
treatment in the community after myocardial infarction; we esti-
mated the effect of statin use on subsequent all cause mortality
and cardiovascular recurrence; and we compared the sociode-
mographic profile and clinic outcome between these community
based patients and clinical trial patients.
Methods
We carried out a cohort study in the population (about 400 000,
mixed urban and rural) of Tayside in Scotland, using the record
linkage database of the Tayside medicine monitor unit. The data-
base has been described previously.7 It contains several data sets,
including all dispensed community prescriptions, hospital
discharge data, mortality data, biochemistry data, sociodemo-
graphic descriptors, and other data that are linked by a unique
patient identifier, the community health index number. The data
have been validated by inspection of general practitioners’
records8 9 and made anonymous for the purposes of research.
Study population and patients
The study population was composed of all residents of Tayside
who were registered with a general practitioner between 1993
and 2001 inclusive (the “study window”), or from 1 January 1993
until their date of death if they died before the end of the study
window.
The study patients were composed of those people in the
study population who were discharged from Tayside hospitals
during the study window with an incident myocardial infarction.
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We divided patients into two groups after their hospital episode:
statin users and non-statin users.
Outcomes
The study outcomes were all cause mortality and cardiovascular
events, defined as a new non-fatal myocardial infarction or
cardiovascular mortality during the follow-up period. We
defined all cause mortality from mortality data from the General
Register Office and cardiovascular mortality as ICD-9 codes
390-459 and ICD-10 codes I00-I99.
Statistical analysis
We summarised data as means with standard deviations for con-
tinuous variables and as numbers (percentages) of subjects for
categorical variables. We used 2 and t tests to determine signifi-
cant differences. We also used Cochran-Armitage trend tests if
there were more than two categorical variables. In the analyses of
the outcomes we calculated adjusted hazard ratios with 95%
confidence intervals in Cox regression models with a time
dependent variable for statin use. The other covariates in the
models were age, sex, Carstairs deprivation category,10 and the
different types of cardiovascular co-medication during the
follow-up period:  blockers, angiotensin converting enzyme
(ACE) inhibitors, other antihypertensive drugs, antiplatelet
drugs, nitrates, warfarin, calcium channel blockers, hormone
replacement therapy, oral contraceptives, steroids, non-steroidal
anti-inflammatory drugs, disease modifying antirheumatic
drugs, previous disease histories of angina, stroke, heart failure,
peripheral vascular disease, diabetes mellitus, obstructive airway
disease, cancer, renal failure, and rheumatoid arthritis. We used
SAS, version 8.0 (SAS Institute, Cary, North Carolina, USA) for
all statistical analyses.
Results
A total of 4892 patients were included in the study. Of these,
2463 (50.3%) were treated with statins during an average
follow-up of 3.7 years. In the group treated with statins, 319
patients died (age adjusted rate 4.1 per 100 person years, 95%
confidence interval 3.2 to 4.9), and in the group not treated with
statins 1200 died (12.7 per 100 person years (11.1 to 14.3)). Table
1 shows the characteristics of statin users and non-users. Statin
use was more common in younger patients. Men were more
likely to be prescribed statins than women. Statin use rose
significantly from 3.1% in 1993 to 62.9% in 2001 (trend test,
P < 0.001). Statin use in older patients also rose over the study
period. However, statin use did not change significantly between
the sexes or with social deprivation.
Five statins (atorvastatin, cerivastatin, fluvastatin, pravastatin,
and simvastatin) were available during the study period, and sim-
vastatin was the most commonly used statin in Tayside patients.
About 80% of statin use was simvastatin, at a median daily dose
of 10 mg.
Proportions of older and female patients in the community
in Tayside were higher than in clinical trials (mean age 67.8 (62.9
for statin users and 72.7 for non-users) v 59.8; women 39.6%
(37.1 for statin users and 42.1 for non-users) v 16.9%,
respectively). Table 2 shows the details of the multivariate analy-
sis. Statin reduced all cause mortality by 31% (95% confidence
interval 20% to 41%) and recurrent myocardial infarction or car-
diovascular death by 18% (5% to 29%). Antiplatelet drugs, 
blockers, nitrates, calcium blockers, and angiotensin converting
enzyme inhibitors were also each independently associated with
diminished risk except antihypertensive drugs and warfarin.
Compared with patients who had had a myocardial infarction
who did not take any cardiovascular drugs, statin users who took
up to two other cardiovascular drugs had lower risks of
cardiovascular events (hazard ratio 0.70, 95% confidence interval
0.50 to 0.97 for statin plus one cardiovascular drug and 0.73, 0.58
to 0.91 for statin plus two cardiovascular drugs). The risk of car-
diovascular events did not differ between those statin users who
took more than two additional cardiovascular drugs and those
post-myocardial infarction patients who received no drug
treatments.
We also did subgroup analyses of older patients (aged ≥ 65)
and women. In the group of women, 633 patients died (crude
rate 9.1 per 100 person years, 8.5 to 9.8), and in the group of
older patients, 1286 died (13.0 per 100 person years, 12.3 to
13.6). The adjusted hazard ratios of mortality in patients receiv-
ing statin treatment were 0.63 (0.49 to 0.80) for female and 0.72
(0.61 to 0.84) for older patients (table 2). The numbers needed to
treat with statin for 3.7 years for all cause mortality were 21 for
overall, 20 for women, and 20 for older people (for non-fatal
myocardial infarction, the numbers needed to treat were 35, 20,
and 35, respectively).
Table 1 Distribution of statin use in patients after myocardial infarction,
Tayside, 1993-2001. Values are numbers (percentages) of patients unless
otherwise indicated
Group treated with
statins (n=2463)
Group not treated with
statins (n=2429)
P value (2
test)
Age:*
<45 145 (5.9) 35 (1.4) <0.001†
45-54 420 (17.1) 160 (6.6)
55-64 745 (30.3) 334 (13.8)
65-74 786 (31.9) 708 (29.2)
75+ 367 (14.9) 1192 (49.1)
Sex:
Male 1550 (62.9) 1406 (57.9) <0.001†
Female 913 (37.1) 1023 (42.1)
Deprivation category:‡
1 (least deprived) 184 (7.5) 144 (6.0) =0.004†
2 373 (15.2) 401 (16.6)
3 595 (24.3) 639 (26.4)
4 470 (19.2) 473 (19.5)
5 253 (10.3) 280 (11.6)
6 (most deprived) 578 (23.5) 481 (19.9)
Cardiovascular drug use during follow up:
 blockers 1705 (69.2) 805 (33.1) <0.001
Angiotensin converting
enzyme inhibitors
1414 (57.4) 739 (30.4) <0.001
Antihypertensive drugs 1151 (46.7) 1271 (52.3) <0.001
Antiplatelets 2193 (89.0) 1591 (65.5) <0.001
Nitrates 2024 (82.2) 1510 (62.7) <0.001
Calcium blockers 1033 (41.9) 778 (32.0) <0.001
Warfarin 253 (10.3) 232 (9.6) =0.399
Comorbidity:
Diabetes mellitus 327 (13.3) 420 (17.3) <0.001
Obstructive airway
disease
12 (0.5) 31 (1.3) =0.003
Cancer 33 (1.3) 76 (3.13) <0.001
Renal failure 5 (0.2) 6 (0.3) =0.745
Rheumatoid arthritis 9 (0.4) 5 (0.2) =0.296
Number of types of cardiovascular drugs used:
Statin plus one drug 63 (2.6) — —
Statin plus two drugs 196 (8.0) — —
Statin plus three or
more drugs
2195 (89.1) — —
*Trend test, P<0.001.
† Overall 2 test between the group treated with statins and the group not treated with
statins.
‡For 4871 subjects.
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Discussion
The beneficial effects of statins can be extended to all patients
with coronary heart disease, including older patients and
women.
Observational studies versus randomised trials
In drug treatment research, observational studies can have
advantages over randomised controlled trials as they often have
large sample sizes and can be more representative of the general
population.11 Although randomised controlled trials are the gold
standard for judging efficacy, well designed observational studies
can examine the findings from randomised controlled trials and
assess the effectiveness of drug treatment in routine clinical
practice. However, it is important to be aware of “confounding by
indication” in making comparisons between patients prescribed
and not prescribed specific treatments.12 This phenomenon
arises because the risk of bad outcomes is intrinsically higher in
patients selected for treatment and because most treatments
reduce, but do not remove, risk. Thus, comparisons of treated
patients with not treated patients may spuriously imply that drug
treatments are actually harmful. Although our study sought to
minimise this effect by studying only patients who had had a
myocardial infarction, all of whom had a strong indication to
receive a statin,13 only half were treated, which implies that some
form of selection was involved. The untreated patients were
older, more likely to be women, and to have more comorbidity
but fewer concurrent cardiovascular drugs (table 1).
Trial versus “real world” population differences
We compared the sociodemographic profile and clinical
outcomes between community based patients and patients from
randomised controlled trials. We found that older patients and
women made up a bigger proportion of the population treated
in routine practice than randomised controlled trials, which
focused mainly on younger and male patients.
Efficacy versus effectiveness
Compared with the efficacy findings of clinical trials, the
effectiveness of drugs in observational analysis of clinical
practice is expected to be reduced. This arises because of inaccu-
rate diagnosis, lack of drug dose titration, confounding by
indication, less than perfect adherence to treatment by patients
and to guidelines by prescribers.14 Despite these potential
influences, we found that the benefits of statins observed in our
community patients were similar to those observed in
randomised controlled trials (0.69, 95% confidence interval 0.59
to 0.80 v 0.79, 0.73 to 0.85). The numbers needed to treat for sta-
tin treatment in the community were also similar to those
reported in clinical trials.1–3
Concurrent drug use
In our study, use of  blockers, antiplatelet drugs, and
angiotensin converting enzyme inhibitors was independently
associated with lower risk of mortality and cardiovascular
outcomes, as others have found.15 16 These findings support the
notion that some of the different treatments available for
secondary prevention do have independent effects and that their
combined use may result in synergistic reductions in clinical out-
comes.17 Interestingly, patients taking warfarin did not experi-
ence any independent reduction in risk of recurrence or death,
perhaps owing to confounding or small numbers. Our analysis
of the combined effects of cardiovascular drugs shows that
patients who took one or two additional drugs had lower risks of
death and recurrent myocardial infarction, which indicates that
additional treatments are synergistic. However, the risks of death
and recurrent myocardial infarction among patients who
received a statin and more than two other cardiovascular drugs
were similar to the risks in patients after a myocardial infarction
who did not receive any drugs. This probably reflects confound-
ing by disease severity in those patients who took three or more
drugs, resulting in any synergistic effects of drug treatments
Table 2 Adjusted hazard ratios with 95% confidence intervals for cardiovascular recurrence and all cause mortality after myocardial infarction in the
community, 1993-2001
Predictor
All cause mortality Non-fatal myocardial infarction or death from cardiovascular disease
Overall Women Older people Overall Women Older people
Sex (male v female) 1.19 (1.07 to 1.33) to 1.15 (1.03 to 1.29) 1.11 (1.00 to 1.24) to 1.11 (0.99 to 1.25)
Age:
<45 1.00 1.00 to 1.00 1.00 —
45-54 0.96 (0.48 to 1.94) 1.40 (0.18 to 11.24) 0.99 (0.60 to 1.61) 0.55 (0.19 to 1.53)
55-64 1.58 (0.83 to 3.02) 2.91 (0.40 to 21.37) 1.26 (0.79 to 2.00) 0.79 (0.31 to 2.02)
65-74 2.57 (1.36 to 4.84) 3.26 (0.45 to 23.59) 1.59 (1.01 to 2.51) 0.79 (0.32 to 1.99)
≥75 3.57 (1.90 to 6.73) 4.50 (0.62 to 32.50) 1.90 (1.20 to 2.99) 0.95 (0.38 to 2.38)
Deprivation category:
1 (least deprived) 1.00 1.00 1.00 1.00 1.00 1.00
2 1.13 (0.89 to 1.43) 0.93 (0.66 to 1.32) 1.10 (0.86 to 1.40) 1.14 (0.90 to 1.43 0.88 (0.62 to 1.24) 1.04 (0.81 to 0.34)
3 1.18 (0.95 to 1.48) 0.92 (0.65 to 1.29) 1.19 (0.95 to 1.50) 1.12 (0.90 to 1.39 0.75 (0.53 to 1.06) 1.06 (0.84 to 1.35)
4 1.37 (1.09 to 1.72) 1.13 (0.81 to 1.59) 1.30 (1.03 to 1.66) 1.24 (0.99 to 1.56 0.92 (0.65 to 1.30) 1.13 (0.88 to 1.44)
5 1.39 (1.09 to 1.78) 1.03 (0.70 to 1.50) 1.29 (1.00 to 1.68) 1.34 (1.06 to 1.71) 0.92 (0.63 to 1.36) 1.15 (0.88 to 1.50)
6 (most deprived) 1.27 (1.01 to 1.60) 0.97 (0.68 to 1.37) 1.24 (0.97 to 1.58) 1.21 (0.97 to 1.52) 0.86 (0.60 to 1.21) 1.12 (0.88 to 1.44)
Statins 0.69 (0.59 to 0.80) 0.63 (0.49 to 0.80) 0.72 (0.61 to 0.84) 0.82 (0.71 to 0.95) 0.69 (0.54 to 0.88) 0.84 (0.71 to 0.99)
 blockers 0.38 (0.33 to 0.43) 0.46 (0.37 to 0.56) 0.39 (0.34 to 0.45) 0.40 (0.35 to 0.46) 0.48 (0.39 to 0.59) 0.46 (0.40 to 0.53)
Angiotensin converting
enzyme inhibitors
0.54 (0.48 to 0.61) 0.55 (0.45 to 0.66) 0.56 (0.50 to 0.64) 0.57 (0.50 to 0.64) 0.64 (0.53 to 0.78) 0.61 (0.54 to 0.70)
Nitrates 0.68 (0.61 to 0.77) 0.68 (0.57 to 0.82) 0.66 (0.58 to 0.75) 0.78 (0.69 to 0.88) 0.78 (0.65 to 0.94) 0.75 (0.65 to 0.85)
Calcium blockers 0.76 (0.67 to 0.86) 0.74 (0.61 to 0.89) 0.73 (0.65 to 0.83) 0.79 (0.70 to 0.89) 0.75 (0.62 to 0.91) 0.76 (0.66 to 0.87)
Antihypertensive drugs 1.14 (1.01 to 1.29) 0.83 (0.70 to 0.99) 1.13 (1.00 to 1.28) 0.90 (0.80 to 1.02) 0.72 (0.60 to 0.86) 0.91 (0.80 to 1.03)
Antiplatelet drugs 0.44 (0.39 to 0.50) 0.49 (0.41 to 0.58) 0.41 (0.36 to 0.47) 0.42 (0.37 to 0.47) 0.44 (0.37 to 0.53) 0.39 (0.34 to 0.45)
Warfarin 0.97 (0.84 to 1.14) 0.94 (0.74 to 1.20) 0.89 (0.75-1.06) 0.93 (0.78 to 1.10) 0.84 (0.64 to 1.09) 0.86 (0.71 to 1.04)
Other covariates included in the multivariate analysis: non-steroidal anti-inflammatory drugs, disease modifying antirheumatic drugs, hormone replacement therapy, and oral contraceptives,
steroids, previous cardiovascular disease, and comorbidity (diabetes, obstructive airway disease, cancer, renal failure, rheumatoid arthritis).
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being obscured by the intrinsically higher risk of patients treated
with more than two additional drugs.
Prescribing of statins has clearly become more common in
Tayside in recent years. From 2000, more than 60% of patients
after a myocardial infarction in Tayside were prescribed statins.
This is a similar proportion to that seen in the second European
action on secondary prevention by intervention to reduce events
(EUROASPIRE II) study18 across nine European countries. Two
large clinical trials (the heart protection study19 and the prospec-
tive study of pravastatin in the elderly at risk (PROSPER) study20)
were published in 2002, which were outside the timeframe of our
study. These trials were relatively inclusive in respect of women
and older patients. However, the results were broadly in accord
with those observed in our study cohorts.
Limitations of the study
Our study has some limitations. Firstly, we assumed that if a pre-
scription was filled then patients would comply with treatment,
but we had no way of knowing whether patients actually took
their treatment. We found that men had higher risk of cardiovas-
cular events than women. This may be partly explained by com-
pliance differences between the sexes.21 Secondly, we were
limited by the number of covariates on which we had data. Con-
sequently we were not able to adjust for smoking, obesity, and
exercise. However, we used the Carstairs socioeconomic depriva-
tion score as a surrogate, which provides adjustment for at least
some of these factors.22
Strength of the study
A strength of our study is the population based cohort design,
with complete follow-up over the study period. This approach
allows a real population to be studied that represents all
socioeconomic groups in a universal healthcare coverage
scheme.23
Conclusion
About half of patients were taking statins during the study
period. Statin use increased from 3.1% for 1993 to 62.9% for
2001. Statin users tended to be younger than non-users and
tended to be prescribed more cardiovascular co-medication.
Although co-medication provided benefits, statins were inde-
pendently effective, reducing the likelihood of both the
combined cardiovascular outcome and all cause mortality. Older
patients and women, who were not well represented in trials, had
similar benefit to other people.
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What is already known on this topic
Trials of the secondary prevention of cardiovascular disease
with statins have been biased against the inclusion of older
and female patients
Meta-analyses of secondary prevention statin trials have
shown consistent beneficial effects on cardiovascular
outcome
What this study adds
In comparison with the patients recruited into clinical trials,
older patients and female patients were represented more
frequently in the population of patients treated with statins
in Tayside (mean age 67.8 v 59.8; women 39.6% v 16.9%,
respectively).The overall effects of statins in routine clinical
practice were consistent with, and similar to, those reported
in clinical trials
The effects of statins for all cause mortality in women and
older patients who were not well represented in trials were
similar to the effects seen in subjects included in trials
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